April 07, 2026

Cancer Is Coming for Younger Adults — and the Field Isn’t Ready

The epidemiological tools built for midlife disease are straining to explain a generational shift

Conexiant

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

April 06, 2026

What Reviews May Miss About Prolonged Grief Disorder

When targeted evidence gets diluted, effective treatments for prolonged grief disorder may be harder to see—and use.

Conexiant

April 06, 2026

UVB and Psoriasis: More Than Immunosuppression

UVB's benefits may run deeper than inflammation suppression—cholesterol metabolism could be a key link.

Conexiant

April 01, 2026

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.

The Medicine Maker

April 01, 2026

Prednisolone Linked to Metabolic Benefits

A randomized crossover trial found slower bone turnover and no safety differences compared with standard hydrocortisone regimens

Conexiant

April 01, 2026

When Vision Becomes a Casualty of War

Why ophthalmic care and resources are desperately needed in Gaza right now

The Ophthalmologist

March 31, 2026

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...

The ASCO Post

March 31, 2026

"We Need Better Answers in Glaucoma"

Leading 2026 Power Lister Gus Gazzard on collaboration, data quality, and trial design

The Ophthalmologist

March 30, 2026

GlycoRNA Comes into Focus with Mass Spectrometry Blueprint

New review maps analytical workflows to decode a surprising class of sugar-coated RNA

The Analytical Scientist